
You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Filters
Status
Categories
- Remove Advertising filter Advertising (2)
- Remove Australian Register of Therapeutic Goods (ARTG) filter Australian Register of Therapeutic Goods (ARTG) (1)
- Remove Biologicals filter Biologicals (2)
- Complementary medicines (7) Apply Complementary medicines filter
- Fees/Payments (1) Apply Fees/Payments filter
- Remove Import/Export filter Import/Export (1)
- Labelling/Packaging (1) Apply Labelling/Packaging filter
- Legislation (3) Apply Legislation filter
- Listed medicines (2) Apply Listed medicines filter
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Medical devices safety (1) Apply Medical devices safety filter
- Medicines (2) Apply Medicines filter
- Medicines safety (1) Apply Medicines safety filter
- Remove OTC medicines filter OTC medicines (12)
- Other therapeutic goods (1) Apply Other therapeutic goods filter
- Prescription medicines (5) Apply Prescription medicines filter
- Scheduling (55) Apply Scheduling filter
- Therapeutic Goods Administration (TGA) (2) Apply Therapeutic Goods Administration (TGA) filter
- Therapeutic goods regulation (2) Apply Therapeutic goods regulation filter
- (-) Remove Biologicals filter Biologicals
- (-) Remove Advertising filter Advertising
- (-) Remove Australian Register of Therapeutic Goods (ARTG) filter Australian Register of Therapeutic Goods (ARTG)
- (-) Remove OTC medicines filter OTC medicines
- (-) Remove Import/Export filter Import/Export
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Lidocaine (lignocaine)
Closed on 18 May 2021
Proposal to remove redundant processes for entering certain formulation information into a therapeutic goods application
Closed on 24 February 2021
Export of therapeutic goods from Australia
Closed on 3 February 2020
The Scheduling Policy Framework and Advertising of Pharmacist-only medicines (Schedule 3 substances)
Closed on 28 April 2017
Loratadine and desloratadine: proposed advisory statements for medicines
Closed on 7 December 2012
Fexofenadine and loperamide: proposed advisory statements for medicines
Closed on 4 June 2012
Public access to information contained in ARTG entries for therapeutic goods
Closed on 3 February 2006
Regulation of new excipients in topical non-prescription medicines
Closed on 16 December 2005